Declerck Paul J, Gils Ann, De Taeye Bart
Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Campus Gasthuisberg, O&N2 Herestraat, Leuven, Belgium.
Methods Enzymol. 2011;499:77-104. doi: 10.1016/B978-0-12-386471-0.00005-5.
Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) and therefore plays an important role in the plasminogen/plasmin system. PAI-1 is involved in a variety of cardiovascular diseases (mainly through inhibition of t-PA) as well as in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vitronectin). PAI-1 is a unique member of the serpin superfamily, exhibiting particular unique conformational and functional properties. Since its involvement in various biological and pathophysiological processes PAI-1 has been the subject of many in vivo studies in mouse models. We briefly discuss structural and physiological differences between human and mouse PAI-1 that should be taken into account prior to extrapolation of data obtained in mouse models to the human situation. The current review provides an overview of the various models, with a focus on cardiovascular disease and cancer, using wild-type mice or genetically modified mice, either deficient in PAI-1 or overexpressing different variants of PAI-1.
纤溶酶原激活物抑制剂-1(PAI-1)是组织型纤溶酶原激活物(t-PA)和尿激酶型纤溶酶原激活物(u-PA)的主要抑制剂,因此在纤溶酶原/纤溶酶系统中发挥重要作用。PAI-1参与多种心血管疾病(主要通过抑制t-PA)以及细胞迁移和肿瘤发展(主要通过抑制u-PA并与玻连蛋白相互作用)。PAI-1是丝氨酸蛋白酶抑制剂超家族的独特成员,具有特殊的独特构象和功能特性。自从其参与各种生物学和病理生理过程以来,PAI-1一直是许多小鼠模型体内研究的主题。我们简要讨论了人类和小鼠PAI-1之间的结构和生理差异,在将小鼠模型中获得的数据外推至人类情况之前应予以考虑。本综述概述了使用野生型小鼠或基因改造小鼠(PAI-1缺陷或过表达PAI-1不同变体)的各种模型,重点关注心血管疾病和癌症。